Global investment firm Carlyle has announced a strategic partnership with CureApp, Inc., a leading Japanese medical technology startup and prescription digital therapeutics provider, through an acquisition of a significant minority stake in the company.  

The investment is part of CureApp’s Series G funding, whereby Carlyle will be investing JPY 7 billion in the company. This brings the total amount of capital raised by CureApp to approximately JPY 13.4 billion. Carlyle will have one board seat as part of the transaction.

CureApp's hypertension prescription digital therapeutic (PDT) received regulatory approval in Japan in April 2022 and is the first-of-its-kind globally; while its smoking cessation treatment app was the first to receive regulatory approval in Japan in 2020. 

The strategic growth investment by Carlyle will help support CureApp in the rollout of its hypertension PDT app and enable the company to advance its digital therapeutics development pipeline. The CureApp management team will also be able to leverage the strength of Carlyle’s global healthcare sector experience as it looks to deepen its sales and distribution network and strengthen its marketing and product development platforms in Japan, and expand globally in the future.